A novel chiral metal‐organic framework (MOF) organocatalyst has been developed, based on readily available MIL‐101 and the chiral primary diamine (1R,2R)‐1,2‐diphenylethylenediamine, by the post‐synthetic modification. Over the developed chiral heterogeneous catalyst the asymmetric synthesis of (S)‐warfarin with high enantioselectivity can be fulfilled on a gram‐scale (2.8 g) with excellent yield (92%)
secondary amine amide catalysts were developed for the asymmetric Michaeladdition of 4-hydroxycoumarin to α,β-unsaturated ketones. A series of important biologically and pharmaceutically active compounds were obtained in excellent yields (up to 99 %) with high enantioselectivities (up to 89 % ee) under mild conditions. In addition, enantiopure product could be obtained by a single recrystallization
Chiral primary amino amide organocatalysts were designed and synthesized as new organocatalysts for the enantioselective Michael addition of 4-hydroxycoumarin with alpha,beta-unsaturated ketones to produce chiral warfarin (up to 56% ee with up to 92% yield).